Literature DB >> 1350265

The human fumarylacetoacetase gene: characterisation of restriction fragment length polymorphisms and identification of haplotypes in tyrosinemia type 1 and pseudodeficiency.

H Rootwelt1, E A Kvittingen, K Høie, E Agsteribbe, M Hartog, H van Faassen, R Berger.   

Abstract

Deficiency of human fumarylacetoacetase (FAH) activity results in hereditary tyrosinemia type I. Using the restriction enzymes BglII, KpnI and StuI and a 1.3-kb cDNA probe for the FAH gene, we have found 6 restriction fragment length polymorphisms (RFLPs). These RFLPs were utilised in 3 tyrosinemia families in which one or both parents are carriers of both a tyrosinemia and a pseudodeficiency gene for FAH. Full information was obtained in two of these families. The polymorphisms identified 6 haplotypes. The haplotype distribution was significantly different in 32 unrelated tyrosinemia patients compared with a reference population of 100 individuals. The combined polymorphism information content was 0.77.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1350265     DOI: 10.1007/bf00217128

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  12 in total

1.  Hereditary tyrosinemia type I: lack of correlation between clinical findings and amount of immunoreactive fumarylacetoacetase protein.

Authors:  E A Kvittingen; H Rootwelt; T van Dam; H van Faassen; R Berger
Journal:  Pediatr Res       Date:  1992-01       Impact factor: 3.756

2.  TaqI RFLP for the human fumarylacetoacetate hydrolase (FAH) gene.

Authors:  S I Demers; D Phaneuf; R M Tanguay
Journal:  Nucleic Acids Res       Date:  1991-03-25       Impact factor: 16.971

3.  KpnI and RsaI RFLPs for the human fumarylacetoacetate hydrolase (FAH) gene.

Authors:  S I Demers; R M Tanguay
Journal:  Nucleic Acids Res       Date:  1991-04-25       Impact factor: 16.971

4.  Type I tyrosinemia: lack of immunologically detectable fumarylacetoacetase enzyme protein in tissues and cell extracts.

Authors:  R Berger; H Van Faassen; J W Taanman; H De Vries; E Agsteribbe
Journal:  Pediatr Res       Date:  1987-10       Impact factor: 3.756

5.  Bg1II RFLP for the human fumarylacetoacetate hydrolase (FAH) gene.

Authors:  S I Demers; R M Tanguay
Journal:  Nucleic Acids Res       Date:  1991-04-25       Impact factor: 16.971

6.  The pre- and post-natal diagnosis of tyrosinemia type I and the detection of the carrier state by assay of fumarylacetoacetase.

Authors:  E A Kvittingen; E Brodtkorb
Journal:  Scand J Clin Lab Invest Suppl       Date:  1986

Review 7.  Construction of a genetic linkage map in man using restriction fragment length polymorphisms.

Authors:  D Botstein; R L White; M Skolnick; R W Davis
Journal:  Am J Hum Genet       Date:  1980-05       Impact factor: 11.025

8.  Stable isotope dilution analysis of succinylacetone using electron capture negative ion mass fragmentography: an accurate approach to the pre- and neonatal diagnosis of hereditary tyrosinemia type I.

Authors:  C Jakobs; L Dorland; B Wikkerink; R M Kok; A P de Jong; S K Wadman
Journal:  Clin Chim Acta       Date:  1988-02-15       Impact factor: 3.786

9.  Different molecular basis for fumarylacetoacetate hydrolase deficiency in the two clinical forms of hereditary tyrosinemia (type I).

Authors:  R M Tanguay; J P Valet; A Lescault; J L Duband; C Laberge; F Lettre; M Plante
Journal:  Am J Hum Genet       Date:  1990-08       Impact factor: 11.025

10.  Cloning and expression of the cDNA encoding human fumarylacetoacetate hydrolase, the enzyme deficient in hereditary tyrosinemia: assignment of the gene to chromosome 15.

Authors:  D Phaneuf; Y Labelle; D Bérubé; K Arden; W Cavenee; R Gagné; R M Tanguay
Journal:  Am J Hum Genet       Date:  1991-03       Impact factor: 11.025

View more
  6 in total

1.  Therapeutic trials in the murine model of hereditary tyrosinaemia type I: a progress report.

Authors:  M Grompe; K Overturf; M al-Dhalimy; M Finegold
Journal:  J Inherit Metab Dis       Date:  1998-08       Impact factor: 4.982

2.  Identification of a frequent pseudodeficiency mutation in the fumarylacetoacetase gene, with implications for diagnosis of tyrosinemia type I.

Authors:  H Rootwelt; E Brodtkorb; E A Kvittingen
Journal:  Am J Hum Genet       Date:  1994-12       Impact factor: 11.025

3.  Novel splice, missense, and nonsense mutations in the fumarylacetoacetase gene causing tyrosinemia type 1.

Authors:  H Rootwelt; R Berger; G Gray; D A Kelly; T Coşkun; E A Kvittingen
Journal:  Am J Hum Genet       Date:  1994-10       Impact factor: 11.025

4.  Hereditary tyrosinemia type I: strong association with haplotype 6 in French Canadians permits simple carrier detection and prenatal diagnosis.

Authors:  S I Demers; D Phaneuf; R M Tanguay
Journal:  Am J Hum Genet       Date:  1994-08       Impact factor: 11.025

5.  Tyrosinemia type 1--complex splicing defects and a missense mutation in the fumarylacetoacetase gene.

Authors:  H Rootwelt; T Kristensen; R Berger; K Høie; E A Kvittingen
Journal:  Hum Genet       Date:  1994-09       Impact factor: 4.132

6.  Two missense mutations causing tyrosinemia type 1 with presence and absence of immunoreactive fumarylacetoacetase.

Authors:  H Rootwelt; J Chou; W A Gahl; R Berger; T Coşkun; E Brodtkorb; E A Kvittingen
Journal:  Hum Genet       Date:  1994-06       Impact factor: 4.132

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.